Cotinga Pharmaceuticals Inc (COTQF)
0.0001
0.00 (0.00%)
USD |
OTCM |
May 17, 16:00
Cotinga Pharmaceuticals Research and Development Expense (Quarterly): 0.1096M for Jan. 31, 2020
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| January 31, 2020 | 0.1096M |
| October 31, 2019 | 0.1197M |
| July 31, 2019 | 0.1257M |
| April 30, 2019 | 0.0945M |
| January 31, 2019 | 0.1022M |
| October 31, 2018 | 0.1027M |
| July 31, 2018 | 0.2948M |
| April 30, 2018 | 0.4276M |
| January 31, 2018 | 0.4431M |
| October 31, 2017 | 0.7956M |
| July 31, 2017 | 0.5047M |
| April 30, 2017 | 0.5147M |
| January 31, 2017 | 0.5128M |
| October 31, 2016 | 0.5667M |
| July 31, 2016 | 0.474M |
| April 30, 2016 | 0.3455M |
| January 31, 2016 | 0.2891M |
| October 31, 2015 | 0.2648M |
| July 31, 2015 | 0.2395M |
| April 30, 2015 | 0.3362M |
| January 31, 2015 | 0.2967M |
| October 31, 2014 | 0.3214M |
| July 31, 2014 | 0.2172M |
| April 30, 2014 | 0.5371M |
| January 31, 2014 | 0.1716M |
| Date | Value |
|---|---|
| October 31, 2013 | 0.1195M |
| July 31, 2013 | 0.1291M |
| April 30, 2013 | 0.0821M |
| January 31, 2013 | 0.2027M |
| October 31, 2012 | 0.2429M |
| July 31, 2012 | 0.2623M |
| April 30, 2012 | 0.2243M |
| January 31, 2012 | 0.1602M |
| October 31, 2011 | 0.1259M |
| July 31, 2011 | 0.2129M |
| April 30, 2011 | 0.1373M |
| January 31, 2011 | 0.1246M |
| October 31, 2010 | 0.133M |
| July 31, 2010 | 0.1884M |
| April 30, 2010 | 0.1612M |
| January 31, 2010 | 0.2216M |
| October 31, 2009 | 0.2718M |
| July 31, 2009 | 0.376M |
| April 30, 2009 | 0.3401M |
| January 31, 2009 | 0.3954M |
| October 31, 2008 | 0.3186M |
| July 31, 2008 | 0.1319M |
| April 30, 2008 | 0.1358M |
| January 31, 2008 | 0.0125M |
| October 31, 2007 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.1096M
Minimum
Jan 2020
0.1257M
Maximum
Jul 2019
0.1183M
Average
0.1197M
Median
Oct 2019
Research and Development Expense (Quarterly) Benchmarks
| Acasti Pharma Inc | 1.443M |
| Aurinia Pharmaceuticals Inc | 10.23M |
| Edesa Biotech Inc | 1.176M |
| Lexaria Bioscience Corp | 0.2458M |
| Liminal Biosciences Inc (DELISTED) | 3.226M |